The goal of this study is to evaluate the safety and potential effectiveness of the investigational drug (bepranemab) for participants with MCI or mild Alzheimer’s Disease. The study compares the effect of the active study drug bepranemab with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’). Using a placebo will help us identify improvements or side effects which are caused by the active study medication. The study drug is administered through an intravenous (IV) injection.

Alzheimer’s is thought to be caused by an abnormal accumulation of proteins (amyloid and tau) in and around brain cells, which causes damage. Tau is a type of protein that is normally found in neurons, but that has lost its proper shape in Alzheimer’s disease. This abnormal tau spreads through the brain and damages brain cells. Your Alzheimer’s disease is one of several types of disease with abnormal tau. The investigational drug bepranemab is an antibody, which is a specific type of protein. The body’s immune system makes antibodies to help fight infections. Antibodies can also be produced and used as a drug, as is the case with bepranemab. We will research whether this study drug potentially slows or stops the worsening of your Alzheimer’s disease.

You and your study partner, someone who knows you well and can answer questions about your daily functioning, will visit the research center approximately 35 times, during approximately 152 weeks. In addition, you will also have several telephone conversations. The duration of a visit is not always the same because not every visit has the same procedures. Some of these visits may last 6 hours, others up to 3.5 hours. A phone call takes around 15 minutes. The research takes place in Amsterdam, Den Bosch, and Zwolle.

This research is commissioned by UCB Biopharma SRL.

You always decide whether you participate in a study. Participation is always voluntary.

1. You apply via the online form, this is non-binding.
2. After application, you are phoned, this is also an opportunity for you to ask questions. During this conversation, we also ask some questions to see whether you are eligible to participate in research. After this conversation, you determine whether you want to progress to step 3.
3. You receive an email with the request to sign a document in which you give permission to retrieve your medical data.
4. When your medical data shows that you meet the requirements to participate in the study, you are invited to a meeting at our location. During this meeting, you receive information and have the opportunity to ask questions, before you decide to participate in research.
5. If you decide to participate in the study, you sign a form and will start the study within several weeks.

1. You always come first – everything we do revolves around you.
2. Experienced team of doctors, neuropsychologists, and nurses.
3. Open and homely atmosphere – this will make you feel relaxed and right at home.
4. Clarity – expert in medicine research which is why you will be well informed during all steps of the process and can always come to us for questions.
5. Always nearby – 3 locations spread through the Netherlands.

• You may experience benefits from a new treatment.
• You will be monitored by a specialized team of healthcare professionals. They can give you advice and monitor whether there is a change in your daily functioning.
• You make a meaningful contribution to a future without Alzheimer’s.
• You contribute to the advancement of science.

You can participate when:

• You have mild cognitive impairment (MCI) or mild Alzheimer’s disease
• You are between 50 and 80 years old.
• You have someone close to you/a caregiver who can accompany you during the visits to the research center and can answer questions about your health and functioning, among other things.

Are you unsure whether you meet these requirements? Then you can always apply. We will then check together whether you are suitable to participate.